Stay connected. Subscribe to our monthly newsletter.

New Residents of Science Center’s Port Incubator Focus on Health IT and Cancer Treatment

PHILADELPHIA--(December 11, 2014) – Two healthcare IT companies and a biotech startup are the newest members of the entrepreneurial community at the Science Center’s Port business incubator. Denovo Health, LLC. has a desk in the Bullpen coworking space and Smart Activities of Daily Living is occupying a cubical at 3711 Market Street. Oncoceutics is occupying an office at the Hubert J. P. Schoemaker Center for Technology Advancement at 3624 Market Street.

Denovo Health, LLC. is an engagement platform targeting chronic diseases that have a high annual cost per patient. Using mobile apps, digital and physical world interactions and behavioral change tactics, its products target chronic conditions where even marginal improvements in patient engagement drive significant health and financial benefits. Using gamification and personalized experiences, Denovo’s current products benefit both patients and healthcare providers with conditions ranging from glaucoma to rheumatoid arthritis and multiple sclerosis.

Smart Activities of Daily Living (Smart ADL) is developing a digital health technology called Smart Cup that enables patients and clinicians to unobtrusively record and monitor fluid intake for effective clinical and self-care management. The technology Smart ADL employs was originally developed at Drexel University. This is not Smart ADL’s first interaction with the Science Center. The startup was a finalist in the Science Center’s QED Proof of Concept program and received grant-writing support from the Science Center prior to taking space at 3711 Market Street.

Oncoceutics, Inc. is a drug discovery and development company targeting the most potent natural suppressor pathways in human cancer. The company’s lead compound is ONC201, a novel small molecule that possesses strong anti-cancer activity in the most challenging indications in oncology. Oncoceutics application to initiate clinical trials with ONC201 was accepted by the FDA in February, 2014. A series of clinical studies at leading US cancer centers are being activated, all of which are funded by mechanisms that include strategic alliances and competitive grant awards. Oncoceutics has development ties with Penn State and the University of Pennsylvania.

The Science Center’s Port business incubator helps emerging life sciences, physical sciences, and digital technology companies operate and grow through a suite of related programs and facilities. The program provides participants with co‐working spaces, cubicles, fully furnished offices, and/or wet and dry labs directly in the heart of the Science Center’s vibrant urban campus. Beyond the physical infrastructure, Port residents are immediately plugged in to a rich network of resources where they can access the programs, the people and the support that can help grow their businesses. Port resident companies have raised more than $116 million in private capital since 2006.

About the Science Center
The University City Science Center is a dynamic hub for innovation, and entrepreneurship and technology development in the Greater Philadelphia region. It provides business incubation, programming, lab and office facilities, and support services for entrepreneurs, start-ups, and growing and established companies. The Science Center was the first, and remains the largest, urban research park in the United States. Since it was founded in 1963, graduate organizations and current residents of the University City Science Center’s Port business incubators have created more than 15,000 jobs that remain in the Greater Philadelphia region today and contribute more than $9 billion to the regional economy annually. For more information about the Science Center, go to

Media Contact:

Kristen Fitch

Kristen Fitch

Senior Director, Marketing